Dr. Lingfan Xu
PhD Degree at Anhui Medical University. Major: Urology. Research focus: Glutamine metabolism and advanced prostate cancer.
Master Degree at Anhui Medical University. Major: Urology. Thesis topic: Expression and clinical significance of autophagy gene Beclin-1 in prostate cancer
Dr. Lingfan Xu, M.D., PhD. is a resident surgeon at the urology department of the First Affiliated Hospital of Anhui Medical University, Hefei, China, which is a comprehensive hospital.
Dr. Lingfan Xu received his medical degree from Anhui Medical University in Hefei, China (2012). After that, he started his resident career at the urology department of the First Affiliated Hospital of Anhui Medical University. Meanwhile, he completed his Master Degree in Anhui Medical University (China, 2015) where he focused on biomarker development of prostate cancer. Subsequently, he pursued his Ph.D degree, spending most of the time in Pathology Department, Duke University for further molecular cell biology training on advanced prostate cancer under the direction of Dr. Jiaoti Huang. After receiving the Ph.D degree, he continued his scientific research in Duke University as a Research Scholar.
Dr. Lingfan Xu?s research interest is to explore the effect of cancer metabolism on the progression of prostate cancer (especially the therapy-resistant prostate cancer). The final goal is to identify a metabolic pharmacological target beyond androgen receptor signaling pathway which may enable compensatory approaches for the current treatment of therapy-resistant prostate cancer.
The two representative articles from Dr. Lingfan Xu unveil: 1) the mechanism of oncogene MYCN contributing to the resistance of anti-androgen therapy and a novel treatment strategy to the castration-resistant prostate cancer (CRPC) patients with MYCN amplification; 2) the mutation of ATM, a DNA damage repair gene, drives the progression of CRPC by enhancing glycolysis pathway. He also published a review about the current androgen receptor -independent mechanisms and potential treatment of choices for the advanced prostate cancer. In addition, his clinic career as a urologist in the past seven years in China confers him a deep understanding about the nature history of the disease and clinical treatment barriers. The academic achievements so far, together with clinical experience, raise his confidence for further discoveries.